Who is this EPA relevant to?
Trainees, supervisors of training (SOTs), clinical supervisors, pharmacists, multidisciplinary team members and assessors involved in pharmacotherapy decisions.
What evidence could be included?
- Case-based discussions;
- Prescribing reviews;
- Documentation reviews;
- Pharmacist input;
- Supervisor narratives;
- Patient feedback; and
- Other approved WBF evidence.
View the draft of EPA 2
This guideline relates to entrustable professional activity 2 (EPA 2), which focuses on safe pharmacotherapy practice, including prescribing, supervising and tapering analgesic medicines in coordination with other prescribers. The training scripts identify opioid stewardship, deprescribing, balancing risks and coordinating multiple prescribers as examples of high-stakes pain medicine decisions characterised by uncertainty and competing goals.
Other pages you might be interested in
This EPA focuses on the trainee’s ability to conduct a comprehensive assessment of a patient with complex pain, bringing together clinical information, patient history, risk, context and professional judgement.
This EPA focuses on the trainee’s ability to develop and present a coherent pain formulation that integrates clinical reasoning, patient context, risk, uncertainty and interdisciplinary perspectives.
This EPA focuses on the trainee’s ability to develop, communicate and review a pain management plan that is safe, patient-centred, practical and coordinated with relevant members of the care team.